First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits

DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that all subjects treated as part of the first stage of its U.S. Food and Drug Administration (FDA) pivotal study completed their 12-month postoperative visits, a significant milestone in the FDA approval process of its Presbia Flexivue Microlens™. The Presbia Flexivue Microlens is a revolutionary optical lens implant for treating presbyopia, the age-related l